Clinical Trial Update: The Use of DIOVAN to Reduce Post-Cardioversion Recurrence of Atrial Fibrillation Trial (the DRAFT Trial) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating losartan (Diovan) to reduce post-cardioversion recurrence of atrial fibrillation has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• DIOVAN (valsartan)

Snippet

Sponsor: Intermountain Health Care, Inc. | Conditions: Atrial Fibrillation | Phase 4 | Status: TERMINATED